Plozasiran (ARO-APOC3): Audience

Plozasiran is a targeted RNA interference (RNAi) therapy designed to reduce the production of Apolipoprotein-CIII (ApoC3) to treat severe hypertriglyceridemia. It leverages the TRiM™ platform to silence genes responsible for lipid disorders, aiming to restore lipid levels to normal.